Cargando…
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Targeted cancer therapy requires the rapid and accurate identification of genetic abnormalities predictive of therapeutic response. We sought to develop a high-throughput genotyping platform that would allow prospective patient selection to the best available therapies, and that could readily and in...
Autores principales: | Dias-Santagata, Dora, Akhavanfard, Sara, David, Serena S, Vernovsky, Kathy, Kuhlmann, Georgiana, Boisvert, Susan L, Stubbs, Hannah, McDermott, Ultan, Settleman, Jeffrey, Kwak, Eunice L, Clark, Jeffrey W, Isakoff, Steven J, Sequist, Lecia V, Engelman, Jeffrey A, Lynch, Thomas J, Haber, Daniel A, Louis, David N, Ellisen, Leif W, Borger, Darrell R, Iafrate, A John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377316/ https://www.ncbi.nlm.nih.gov/pubmed/20432502 http://dx.doi.org/10.1002/emmm.201000070 |
Ejemplares similares
-
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
por: Tanaka, Shota, et al.
Publicado: (2019) -
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
por: Dias-Santagata, Dora, et al.
Publicado: (2011) -
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019) -
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011) -
Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
por: Deng, Xianming, et al.
Publicado: (2011)